Traws Pharma, Inc. announced on June 22, 2026, its intention to resubmit an updated data package to the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for the planned testing of tivoxavir marboxil. Traws Pharma, Inc. is a pharmaceutical company focused on developing and testing clinical trial testing of drug candidates.

Traws Pharma, Inc. announced on June 12, 2026, that the planned Phase 2a human influenza challenge study for tivoxavir marboxil has been deferred due to a negative review from the United Kingdom's Medicines and Healthcareproducts Regulatory Agency. Traws Pharma, Inc. is a pharmaceutical company focused on developing influenza treatments.